Noven, Novartis Pharma AG, Rhone-Poulenc Rorer deal

Novartis received a sublicense from RPR to market NOVN's Estalis estrogen/progestin transdermal system worldwide except for the U.S. and Japan, and NOVN's Menorest 17-beta-estradiol transdermal patch worldwide except in the U.S., Canada and Japan. NOVN said it will receive $2.7 million from marketing partner RPR as its share of the sublicense fees. ...